Vaccines Market

The report "Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029", (including COVID-19 vaccines) is projected to reach USD 94.9 Billion by 2029 from USD 78.0 Billion in 2024, at a CAGR of 4.0% during the forecast period. Similarly the vaccines market (excluding COVID-19 vaccines) is projected to reach USD 80.3 Billion by 2029 from USD 53.0 Billion in 2024, at a CAGR of 8.7% during the forecast period.

Browse 394 market data Tables and 57 Figures spread through 414 Pages and in-depth TOC on "Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html

Growth in the vaccines market is driven by the rising prevalence of infectious diseases, government immunization programs, and advancements in vaccine technology, including mRNA platforms. Increased R&D investments, collaborations, and funding support further fuel market expansion, particularly in therapeutic vaccines for cancer and autoimmune diseases. However, high development costs, stringent regulations, safety concerns, and production scalability challenges pose significant hurdles. While government initiatives and innovation drive growth, ensuring equitable access and regulatory compliance remains crucial for sustained market momentum.

The conjugate vaccine segment is expected to have the dominant share of the vaccine market (excluding COVID-19 vaccines) in 2023.

Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, inactivated & subunit vaccines, and other vaccine technologies. The conjugate vaccine segment is poised to dominate the 2023 vaccine market (excluding COVID-19 vaccines), driven by its ability to enhance immune recognition of bacterial polysaccharides in infants and young children. The segment's growth is fueled by public-private partnerships, increased government support, and rising investments in vaccine development, particularly in emerging economies. Additionally, robust R&D efforts, strategic collaborations, and favorable regulatory frameworks have solidified the prominence of conjugate vaccines. The expansion of immunization programs in developing regions, coupled with growing awareness of vaccination benefits, further boosts demand. Despite the need for booster shots to maintain immunity, advancements in vaccine technology and the rising prevalence of preventable diseases ensure that conjugate vaccines will continue to play a pivotal role in global healthcare.

The HPV segment is expected to account for the largest share of the disease indication segment in the vaccines market (excluding COVID-19 vaccines) in 2023.

Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, influenza, combination vaccines, pneumococcal disease, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV and other disease indications. HPV vaccines are designed to prevent diseases caused by the human papillomavirus, which is primarily transmitted through sexual contact. The rising prevalence of HPV-related diseases has heightened the focus on developing more effective vaccines. HPV infections are classified into low-risk and high-risk types, with low-risk infections potentially leading to conditions like genital warts, and high-risk infections being associated with various cancers, including cervical, anal, and oral cancers. High-risk HPV infections can cause pre-cancerous changes that may become fatal if not treated early. Numerous organizations are actively working to expand cervical cancer immunization programs worldwide through funding and product approvals. While the HPV segment leads, the RSV vaccine segment is expected to experience significant growth in the coming years, fueled by increased investments and recent regulatory approvals for new vaccines. This growing emphasis on HPV and RSV vaccines underscores the critical role of immunization in addressing these serious health challenges.

The North America region (excluding COVID-19 vaccines) held the largest share of the vaccines market in 2023.

The vaccines market in segmented into North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2023, North America (excluding COVID-19 vaccines) held the largest share of the vaccines market. The region's high prevalence of infectious diseases, coupled with significant investments from government and non-government organizations, has fueled market growth. The rising demand for novel vaccines, driven by the increasing burden of infectious diseases, continues to propel the vaccines market in North America, making it a dominant player in the global landscape. Despite this, Asia Pacific remained the fastest growing region in the vaccines market thoughout the forecast period.

Key players in the vaccines market include GSK plc (UK), Merck & Co., Inc (US) Pfizer Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services, Inc (US), AstraZeneca (UK), Serum Institute Of India Pvt. Ltd (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company Limited (Japan), Panacea Biotec (India), Biological E Limited (India), and Bharat Biotech (India) among others

Don’t miss out on business opportunities in Vaccines Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com